Bellicum Pharmaceuticals

173 articles about Bellicum Pharmaceuticals

• Bellicum to Participate in Two Upcoming Virtual Investor Conferences - Sep 02, 2020

  9/2/2020

  Bellicum Pharmaceuticals, Inc., a leader in developing novel, controllable cellular immunotherapies for cancers, announced that management will participate in two upcoming virtual investor conferences.

• Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 31, 2020

  8/31/2020

  Bellicum Pharmaceuticals, Inc., a leader in developing novel, controllable cellular immunotherapies for cancers, announced equity inducement grants to three new employees consisting of an aggregate of 13,680 stock options.

• Bellicum Reports Second Quarter 2020 Financial Results and Provides Operational Update

  8/6/2020

  Bellicum Pharmaceuticals, Inc., a leader in developing novel, controllable cellular immunotherapies for cancers, reported financial results for the second quarter 2020 and provided an operational update.

• Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 31, 2020

  7/31/2020

  Bellicum Pharmaceuticals, Inc., a leader in developing novel, controllable cellular immunotherapies for cancers, announced equity inducement grants to two new employees consisting of an aggregate of 3,520 stock options.

• Bellicum to Report Second Quarter 2020 Financial Results and Provide Corporate UpdateManagement to host webcast and conference call on Thursday, August 6, 2020 at 5 p.m. ET / 2 p.m. PT

  7/30/2020

  Bellicum Pharmaceuticals, Inc., a leader in developing novel, controllable cellular immunotherapies for cancers, announced it will report financial results for the second quarter 2020 after the close of U.S. markets on Thursday, August 6, 2020.

• Bellicum Receives FDA IND Clearance to Initiate a Phase 1/2 Clinical Trial for BPX-603, a Dual-Switch GoCAR-T® for HER2+ Solid Tumors

  6/15/2020

  Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced clearance by the U.S. Food and Drug Administration (FDA) of its investigational new drug application (IND) for BPX-603. BPX-603 is a GoCAR-T® product candidate targeting solid tumors that express human epidermal growth factor receptor 2 (HER2)

• Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 29, 2020

  5/29/2020

  Bellicum Pharmaceuticals, Inc., a leader in developing novel, controllable cellular immunotherapies for cancers, announced equity inducement grants to one new employee consisting of an aggregate of 16,820 stock options.

• Bellicum to Participate in Two Upcoming Virtual Investor Conferences

  5/27/2020

  Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that management will participate in two upcoming virtual investor conferences. Conference Details: Jefferies Virtual Healthcare Conference Date/Time: Wednesday, June 3, 2020 at 4:00 p.m. EDT Format: Fireside Chat Investor Summit Virtual Summer Summit Date/Time: Wednesday, June 10, 2020 at 3:20 p.m.

• Bellicum Announces Publication of Data for GoCAR-NK™ Cell Program

  5/27/2020

  Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the publication of preclinical data from its GoCAR-NK™ Cell Program in the digital edition of Blood Advances, a journal published by The American Society of Hematology

• Bellicum Reports First Quarter 2020 Financial Results and Provides Operational Update  

  5/7/2020

  Completed $15 million sale of manufacturing, office and laboratory facility to MD Anderson and entered into supply agreement

• Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 30, 2020

  4/30/2020

  Bellicum Pharmaceuticals, Inc., a leader in developing novel, controllable cellular immunotherapies for cancers, announced equity inducement grants to one new employee consisting of an aggregate of 15,000 stock options.

• Bellicum Completes Sale of Houston Facility

  4/15/2020

  Purchase price of $15 million from sale of manufacturing, office and laboratory facility

• Bellicum Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Operational Update

  3/12/2020

  Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial results for the fourth quarter and full year 2019 and provided an operational update.

• Bellicum to Report Fourth Quarter and Full Year 2019 Financial Results and Provide Corporate UpdateManagement to host webcast and conference call on Thursday, March 12, 2020 at 5 p.m. ET / 2 p.m. PT

  3/5/2020

  Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced it will report financial results for the fourth quarter and full year 2019 after the close of U.S. markets on Thursday, March 12, 2020

• Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  2/28/2020

  Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity inducement grants to one new employee consisting of an aggregate of 15,000 stock options.

• Bellicum Announces Reverse Stock Split

  2/5/2020

  HOUSTON, Feb. 05, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM) (“Bellicum” or the “Company”), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that the Company effected a reverse stock split of its issued and outstanding common stock, at a ratio of 1-for-10. The effective time of the reverse stock split will be 5 p.m. ET on February 5, 2020. The Company’s common stock will begin trading on a split-adjusted basis commenci

• Bellicum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

  1/31/2020

  Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that the Compensation Committee of the Board of Directors has approved an inducement award consisting of a stock option to purchase up to 156,000 shares of the Company’s common stock to David E. Strauss.

• Bellicum Presents New Translational Data for BPX-601 at ASCO GI Cancers Symposium

  1/24/2020

  Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today presented new Phase 1 translational results for BPX-601 at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) in San Francisco

• Bellicum Pharmaceuticals Enters into Asset Purchase and Master Services Agreements with MD Anderson

  1/21/2020

  Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced it has entered into an asset purchase agreement under which The University of Texas MD Anderson Cancer Center will acquire Bellicum’s approximately 60,000-square-foot Houston facility, including manufacturing, office and laboratory space, for $15 million.

• Bellicum Pharmaceuticals to Present New Translational Data for BPX-601 at ASCO 2020 Gastrointestinal Cancers Symposium

  1/16/2020

  Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that an abstract on new Phase 1 translational results for BPX-601, its lead GoCAR-T product candidate, has been accepted for poster presentation at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI).